Skip to main content

Table 1 Clinicopathologic data

From: Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy

  No. (n/N) (%)
Patients’ clinical characteristics (N = 18)
Age
 Median (range) 63.2 (55–76)
 Age > 60 years 11/18 (61)
Sex. female 12/18 (67)
Smoking 4/18 (22)
Positive serum tumor markers
 CEA 6/18 (33)
 CA199 9/18 (50)
 CYFRA 21-1 2/18 (11)
 NSE 0/18 (0)
Location
 RLL/RUL/RML 9/18 (50)
 LLL/LUL 9/18 (50)
Size (cm)
 Median (range) 3.1 (1.1–6.6)
pTNM classification
 Stage I/II 12/18 (67)
 Stage III/IV 6/18 (33)
Follow-up (M)
 Median (range) 31 (4–96)
 Died 3/16 (19)
 Alive 13/16 (81)
 Not available 2/16 (12.5)
  1. The clinical characteristics of 18 primary PEACs diagnosed in our medical center from 2008 to 2017 were summarized. The levels of these four tumor markers when patient first visit were compared with the upper limit of normal expression ranges, and the multiples were showed in table. The normal expression ranges of these four tumor markers: CEA, 0–5 μg/L; CA199, 0–37 U/mL; CYFRA21-1, 0–7 μg/L; NSE, 0–30 μg/L; All cases were staged according to the pathological tumor/node/metastasis (pTNM) classification (8th edition) of the IASLC
  2. M male, F female, CEA carcinoembryonic antigen, CA199 carbohydrate antigen, CYFRA21-1 cytokeratin 19 fragment, NSE neuron-specific enolase, RLL right lower lobe, RUL right upper lobe, LLL left lower lobe, LUL left upper lobe, RML right middle lobe, mo month, D died, A alive, NA not available